The Selection and Use of Essential Medicines - WHO Technical Report Series, No. 914: References

The Selection and Use of Essential Medicines - WHO Technical Report Series, No. 914
(2003; 132 pages)

Table of Contents

WHO Expert Committee on the Selection and Use of Essential Medicines
1. Introduction
2. Open session
3. The new procedures for updating and disseminating the Model List
	3.1 Background
	3.2 Key features of the new procedures
	3.3 Review of the new procedures
		3.3.1 Applications for additions
		3.3.2 Applications for deletions
		3.3.3 Selection criteria
	3.4 The WHO model formulary
	3.5 The WHO Essential Medicines Library
4. Other outstanding technical issues
	4.1 Change of name of the Expert Committee
	4.2 Description of essential medicines
	4.3 Role of treatment costs in relation to the Model List
	4.4 Inclusion of additional items in the Model List
5. Format and presentation of the 12th Model List
	5.1 Section headings
	5.2 The core and complementary lists
	5.3 The “square box” symbol
6. Changes made in revising the Model List
	6.1 Applications for additions
		6.1.1 Antiretroviral medicines
		6.1.2 Artemether + lumefantrine (fixed-dose combination)
		6.1.3 α/β-Arteether
		6.1.4 Artemotil (β-arteether)
		6.1.5 Amodiaquine
		6.1.6 Insecticide-treated bednets
		6.1.7 Miconazole nitrate buccal tablets
	6.2 Applications for deletions
	6.3 Other changes
		6.3.1 Meglumine antimoniate
		6.3.2 Antineoplastic and immunosuppressive medicines
		6.3.3 Reserve list medicines
7. Future reviews of sections of the Model List
	7.1 Update on the review of medicines for the treatment of hypertension
	7.2 Review of the core and complementary lists
	7.3 Review of the use of the “square box” symbol
	7.4 Review of injectable medicines
	7.5 Priorities for further systematic reviews
8. Recommendations
	8.1 Procedures for updating and disseminating the Model List of Essential Medicines¹
	8.2 Description of essential medicines
	8.3 Presentation of the 12th Model List
	8.4 Additions and changes to the Model List
	8.5 Deferred applications
	8.6 Rejected applications
	8.7 Priorities for future reviews of sections of the Model List
	8.8 Change of name of the Expert Committee
	8.9 Other recommendations
Acknowledgements
References
Annex 1 The 12th WHO Model List of Essential Medicines
Annex 2 Additional notes on the medicines recommended for inclusion in the 12th WHO Model List of Essential Medicines
Annex 3 The Anatomical Therapeutic Chemical (ATC) classification system¹
Alphabetical list of essential medicinces (with ATC classification codes)

References

1. Pilot procurement, quality and sourcing project: access to HIV/AIDS drugs and diagnostics of acceptable quality, 4th ed. Geneva, World Health Organization, 2002 (regularly updated; available from the Internet at http://www.who.int/medicines/organization/par/edl/access-hivdrugs.shtml).

2. The use of essential drugs. Ninth report of the WHO Expert Committee (including the revised Model List of Essential Drugs). Geneva, World Health Organization, 2000 (WHO Technical Report Series, No. 895).

3. Revised procedures for updating the WHO Model List of Essential Drugs: a summary of proposals and process. Geneva. World Health Organization, 2001 (document EB108/INF.DOC2; available from the Internet at http://www.who.int/gb/).

4. Updating and disseminating the Model List of Essential Drugs: the way forward. Geneva, World Health Organization, 2001 (WHO/EDM discussion paper).

5. Resolution EM/RC48/R2. In: Annual report of the Regional Director for the year 2000 and progress reports. WHO Regional Committee for the Eastern Mediterranean, Forty-eighth Session, Riyadh, Saudi Arabia, October 2001. Alexandria, WHO Regional Office for the Eastern Mediterranean, 2001.

6. WHO medicines strategy: revised procedure for updating WHO’s Model List of Essential Drugs. Geneva, World Health Organization, 2002 (document EB109/8; available from the Internet at http://www.who.int/gb/).

7. WHO medicines strategy: procedure to update and disseminate the WHO Model List of Essential Medicines. In: WHO medicines strategy: revised procedure for updating WHO’s Model List of Essential Drugs. Geneva, World Health Organization, 2002: Annex 1 (document EB109/8; available from the Internet at http://www.who/int/gb/).

8. The use of essential drugs. Seventh report of the WHO Expert Committee. Geneva, World Health Organization, 1997 (WHO Technical Report Series, No. 867).

9. WHO model formulary 2002. Geneva, World Health Organization, 2002.

10. Breastfeeding and maternal medication. Geneva, World Health Organization, 1995 (document WHO/CDR/95.11).

11. The selection of essential drugs. Report of a WHO Expert Committee. Geneva, World Health Organization, 1977 (WHO Technical Report Series, No. 615).

12. The selection of essential drugs. Second report of a WHO Expert Committee. Geneva, World Health Organization, 1979 (WHO Technical Report Series, No. 641).

13. The use of essential drugs. Report of a WHO Expert Committee. Geneva, World Health Organization, 1983 (WHO Technical Report Series, No. 685).

14. WHA28.66. Prophylactic and therapeutic substances. In: Handbook of resolutions and decisions of the World Health Assembly and the Executive Board, Volume II, 1973-1984. Geneva, World Health Organization, 1985:129.

15. WHA31.32. Action programme on essential drugs. In: Handbook of resolutions and decisions of the World Health Assembly and the Executive Board, Volume II, 1973-1984. Geneva, World Health Organization, 1985:129-130.

16. Official Record of the World Health Organization, 226: Annex 13.

17. Guidelines for ATC classification and DDD assignment, 2nd ed. Oslo, WHO Collaborating Centre for Drug Statistics Methodology, 1998.

18. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Geneva, World Health Organization, 2002 (available on the Internet at http://www.who.int/hiv/topics/arv/ISBN9241545674.pdf).

19. The use of essential drugs. Model list of essential drugs (fifth list). Third report of the WHO Expert Committee. Geneva, World Health Organization, 1988 (WHO Technical Report Series, No. 770).

20. Dictionaire Vidal. Paris, Editions du Vidal, 1998.

21. WHO/ISH guidelines for the management of hypertension. Geneva, World Health Organization, 1999.

22. Development of WHO treatment guildelines: recommended process. Geneva, World Health Organization, 2001 (in preparation).